BibTex RIS Cite

Critical considerations in pharmacetical bioequivalence testing

Year 1995, Volume: 11 Issue: 1-2, 55 - 80, 30.03.2015

Umesh Banakar Michael Makoid

Abstract

Keywords

-

Critical Consideration in pharmaceutical bioequivalence testing

Year 1995, Volume: 11 Issue: 1-2, 55 - 80, 30.03.2015

Umesh Banakar Michael Makoid

Abstract

Keywords

-

There are 0 citations in total.

Details

Primary Language English
Journal Section Articles
Authors

Umesh Banakar This is me

Michael Makoid This is me

Publication Date March 30, 2015
Published in Issue Year 1995 Volume: 11 Issue: 1-2

Cite

APA Banakar, U., & Makoid, M. (2015). Critical considerations in pharmacetical bioequivalence testing. Marmara Pharmaceutical Journal, 11(1-2), 55-80. https://doi.org/10.12991/mpj.20066
AMA Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. Marmara Pharm J. April 2015;11(1-2):55-80. doi:10.12991/mpj.20066
Chicago Banakar, Umesh, and Michael Makoid. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal 11, no. 1-2 (April 2015): 55-80. https://doi.org/10.12991/mpj.20066.
EndNote Banakar U, Makoid M (April 1, 2015) Critical considerations in pharmacetical bioequivalence testing. Marmara Pharmaceutical Journal 11 1-2 55–80.
IEEE U. Banakar and M. Makoid, “Critical considerations in pharmacetical bioequivalence testing”, Marmara Pharm J, vol. 11, no. 1-2, pp. 55–80, 2015, doi: 10.12991/mpj.20066.
ISNAD Banakar, Umesh - Makoid, Michael. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal 11/1-2 (April 2015), 55-80. https://doi.org/10.12991/mpj.20066.
JAMA Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. Marmara Pharm J. 2015;11:55–80.
MLA Banakar, Umesh and Michael Makoid. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal, vol. 11, no. 1-2, 2015, pp. 55-80, doi:10.12991/mpj.20066.
Vancouver Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. Marmara Pharm J. 2015;11(1-2):55-80.